ATE435223T1 - Pyrimidin-, chinazolin-, pteridin- und triazinderivate - Google Patents

Pyrimidin-, chinazolin-, pteridin- und triazinderivate

Info

Publication number
ATE435223T1
ATE435223T1 AT07727049T AT07727049T ATE435223T1 AT E435223 T1 ATE435223 T1 AT E435223T1 AT 07727049 T AT07727049 T AT 07727049T AT 07727049 T AT07727049 T AT 07727049T AT E435223 T1 ATE435223 T1 AT E435223T1
Authority
AT
Austria
Prior art keywords
pteridine
quinazoline
pyrimidine
triazine derivatives
compounds
Prior art date
Application number
AT07727049T
Other languages
English (en)
Inventor
Alfred Binggeli
Andreas Christ
Hans-Peter Maerki
Rainer Eugen Martin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE435223T1 publication Critical patent/ATE435223T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Dental Preparations (AREA)
  • Saccharide Compounds (AREA)
AT07727049T 2006-03-27 2007-03-19 Pyrimidin-, chinazolin-, pteridin- und triazinderivate ATE435223T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06111751 2006-03-27
PCT/EP2007/052571 WO2007110340A2 (en) 2006-03-27 2007-03-19 Pyrimidine, quinazoline, pteridine and triazine derivatives

Publications (1)

Publication Number Publication Date
ATE435223T1 true ATE435223T1 (de) 2009-07-15

Family

ID=36997595

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07727049T ATE435223T1 (de) 2006-03-27 2007-03-19 Pyrimidin-, chinazolin-, pteridin- und triazinderivate

Country Status (14)

Country Link
US (1) US7855194B2 (de)
EP (1) EP2001867B1 (de)
JP (1) JP2009531372A (de)
KR (1) KR101084484B1 (de)
CN (1) CN101405284A (de)
AT (1) ATE435223T1 (de)
AU (1) AU2007229555A1 (de)
BR (1) BRPI0710121A2 (de)
CA (1) CA2648025A1 (de)
DE (1) DE602007001463D1 (de)
ES (1) ES2326930T3 (de)
IL (1) IL194057A (de)
MX (1) MX2008012134A (de)
WO (1) WO2007110340A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5577104B2 (ja) * 2007-03-14 2014-08-20 エクセリクシス パテント カンパニー エルエルシー ヘッジホッグ経路の阻害剤
MX2010010975A (es) * 2008-04-07 2010-11-01 Amgen Inc Amino piridinas/pirimidinas gem-disustituidas y espirociclicas como inhibidores de ciclo celular.
EP2605658B1 (de) 2010-08-18 2016-03-23 Merck Sharp & Dohme Corp. Spiroxazolidinonverbindungen
US11110080B2 (en) 2017-03-27 2021-09-07 The Regents Of The University Of Colorado, A Body Corporate Small molecule inhibitors of bacterial efflux pumps and methods of using same
JOP20190284A1 (ar) * 2017-06-14 2019-12-11 Bayer Pharma AG مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس
MX2020006587A (es) 2017-12-22 2020-12-10 Ravenna Pharmaceuticals Inc Derivados de aminopiridina como inhibidores de fosfatidilinositol fosfato cinasa.
KR102328682B1 (ko) 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
BR112022022338A2 (pt) 2020-05-04 2023-01-10 Amgen Inc Compostos heterocíclicos como receptor desencadeador expresso em agonistas de células mieloides 2 e métodos de uso
TW202208355A (zh) 2020-05-04 2022-03-01 美商安進公司 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法
KR20250157553A (ko) 2023-03-27 2025-11-04 가부시키가이샤 스코히아 파마 성장 호르몬 분비 촉진제
WO2025209570A1 (zh) * 2024-04-03 2025-10-09 北京大学 Bet抑制剂及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2121031A1 (en) 1971-04-29 1972-11-02 Dr. Karl Thomae Gmbh, 7950 Biberach Base-substd quinazolines - thrombocyte aggregation inhibitors
CH598231A5 (de) 1973-07-27 1978-04-28 Hoffmann La Roche
US3931181A (en) 1973-07-27 1976-01-06 Hoffmann-La Roche Inc. 2,4-Diamino-5-benzylpyrimidines
US3956495A (en) 1973-10-30 1976-05-11 Eli Lilly And Company 2,4-Diaminoquinazolines as antithrombotic agents
US4309541A (en) 1978-09-20 1982-01-05 Ciba-Geigy Corporation Piperidinyl-lactams
EP0009465A1 (de) 1978-09-20 1980-04-02 Ciba-Geigy Ag N-(1-(4-Amino-2-chinazolinyl)-3- oder -4-piperidyl-lactame, Verfahren zu ihrer Herstellung, sowie pharmazeutische Präparate enthaltend diese Verbindungen
FR2514765A1 (fr) 1981-10-21 1983-04-22 Sanofi Sa Nouveaux derives de la phenyl-4 quinazoline actifs sur le systeme nerveux central
KR100190299B1 (ko) 1990-07-19 1999-06-01 디르크 반테 신규한 옥사졸릴 유도체
FR2669923B1 (fr) 1990-11-29 1993-01-29 Rhone Poulenc Chimie Procede de preparation de composes aromatiques alkoxyles.
TW504510B (en) 1996-05-10 2002-10-01 Janssen Pharmaceutica Nv 2,4-diaminopyrimidine derivatives
PT921116E (pt) 1997-12-04 2003-11-28 Hoffmann La Roche Derivados de n-(4-carbamimido-fenil)-glicinamida
HRP20010427A2 (en) 1998-12-14 2002-06-30 Hoffmann La Roche Phenylglycine derivatives
WO2001032633A1 (de) 1999-11-04 2001-05-10 Basilea Pharmaceutica Ag Substituierte 5-benzyl-2,4-diaminopyrimidine
FR2802206B1 (fr) * 1999-12-14 2005-04-22 Sod Conseils Rech Applic Derives de 4-aminopiperidine et leur utilisation en tant que medicament
FR2807038B1 (fr) 2000-04-03 2002-08-16 Sanofi Synthelabo Nouveaux derives d'indolin-2-one, leur preparation et les compositions pharmaceutiques les contenant
ATE284882T1 (de) 2000-04-27 2005-01-15 Basilea Pharmaceutica Ag Chromenylmethylpyrimidindiamine als antibakterielle wirkstoffe
US6548694B2 (en) 2000-05-23 2003-04-15 Hoffman-La Roche Inc. N-(4-carbamimidoyl-phenyl)-glycine derivatives
DE10228132A1 (de) 2002-06-24 2004-01-22 Arzneimittelwerk Dresden Gmbh Amide cyclischer Aminosäuren als PDE 4 Inhibitoren
EP1571146A4 (de) 2002-12-10 2010-09-01 Ono Pharmaceutical Co Stickstoffhaltige heterocyclischeverbindungen und deren medizinische verwendung
US7560464B2 (en) 2004-04-13 2009-07-14 Icagen, Inc. Polycyclic pyrimidines as potassium ion channel modulators

Also Published As

Publication number Publication date
EP2001867B1 (de) 2009-07-01
KR101084484B1 (ko) 2011-11-21
ES2326930T3 (es) 2009-10-21
US20070225271A1 (en) 2007-09-27
DE602007001463D1 (de) 2009-08-13
BRPI0710121A2 (pt) 2012-07-17
WO2007110340A3 (en) 2007-11-15
MX2008012134A (es) 2008-10-03
US7855194B2 (en) 2010-12-21
AU2007229555A1 (en) 2007-10-04
IL194057A0 (en) 2009-08-03
IL194057A (en) 2012-07-31
KR20080104074A (ko) 2008-11-28
WO2007110340A2 (en) 2007-10-04
JP2009531372A (ja) 2009-09-03
EP2001867A2 (de) 2008-12-17
CA2648025A1 (en) 2007-10-04
CN101405284A (zh) 2009-04-08

Similar Documents

Publication Publication Date Title
ATE435223T1 (de) Pyrimidin-, chinazolin-, pteridin- und triazinderivate
ATE517882T1 (de) Chinolinderivate
TW200833686A (en) Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors
EA200900023A1 (ru) Применение замещенных 2-аминотетралинов для изготовления лекарственного средства для предупреждения, облегчения и/или лечения разных видов боли
TW200612936A (en) Indole derivatives
PH12012501122A1 (en) Pteridinones as inhibitors of polo-like kinase
TNSN08444A1 (en) Bicyclic derivatives as cetp inhibitors
MY155836A (en) Thienopyridone derivatives as amp-activated protein kinase (ampk) activators
IL189191A0 (en) Thiazolyl piperidine derivatives useful as h3 receptor modulators
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
MX2010013682A (es) Derivados de 2,4-diamino-l,3,5-triazina triciclicos utiles para el tratamiento del cancer y trastornos mieloproliferativos.
NO20076060L (no) Piperidin-4-yl-amidderivater og deres anvendelse som SST-reseptor subtype 5-antagonister
MX2009011059A (es) Aminopirimidinas utiles como inhibidores de cinasas.
IL195747A0 (en) Pyrimidine and quinazoline derivatives as modulators of somatostatine receptor activity
TW200616979A (en) Non-nucleoside reverse transcriptase inhibitors
MX2007013624A (es) Inhibidores de proteina cinasa.
IL195016A0 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
TW200626158A (en) Naphthaline derivatives
MX2009012518A (es) Derivados de piperidina 4,4-disubstituidos.
ATE449776T1 (de) Pyrroloä2,3-cüpyridinderivate
TW200637817A (en) 5-aminoindole derivatives
ATE438617T1 (de) Substituierte cyclohexyl-1,4-diamin-derivate
MX2009005242A (es) Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo.
TW200640904A (en) Quinazoline derivatives
DE602007008952D1 (de) Imidazolidinonylaminopyrimidinverbindungen zur behandlung von krebs

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2001867

Country of ref document: EP